Dyslipidemia - Japan Drug Forecast and Market Analysis to 2023
GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast period, resulting in a market value of $37.9bn by 2023, of which 71% will be attributed to branded drug sales ($26.9bn) and 29% to generic drug sales ($11.0bn). The current dyslipidemia market is dominated by the statins, the revolutionary drugs that reduce low-density lipoprotein cholesterol (LDL-C) and that have been proven to reduce the risk of cardiovascular events such as heart attack and stroke. Other major lipid-modulating drugs, such as Zetia (ezetimibe), the fibrates, bile acid sequestrants, omega-3 fish oil agents, and rare-disease therapies comprise the remainder of the current dyslipidemia space. The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales landscape of the dyslipidemia market moving forward.
In the 2013 base year, the only dyslipidemia drugs included in this forecast that were available in Japan were the statins, ezetimibe, and the omega-3 fish oil agents. Of these, the statins contributed to the vast majority of sales, with the drug class contributing $793m, or 76% of the total Japanese market share.
Overview of Dyslipidemia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Japan from 2013-2023.
Analysis of the impact of key events as well the drivers and restraints affecting Japan Dyslipidemia market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Dyslipidemia.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2013-2023 in Japan.